Nanobiotix (NBTX) Competitors

Nanobiotix has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, PTC Therapeutics had 11 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for PTC Therapeutics and 1 mentions for Nanobiotix. PTC Therapeutics' average media sentiment score of 0.72 beat Nanobiotix's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Nanobiotix currently has a consensus price target of $46.67, indicating a potential upside of 45.70%. PTC Therapeutics has a consensus price target of $99.23, indicating a potential upside of 52.59%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Nanobiotix.

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix has a net margin of 0.00% compared to PTC Therapeutics' net margin of -9.17%.

PTC Therapeutics has higher revenue and earnings than Nanobiotix.

Mirum Pharmaceuticals presently has a consensus price target of $154.94, indicating a potential upside of 66.28%. Nanobiotix has a consensus price target of $46.67, indicating a potential upside of 45.70%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Nanobiotix.

38.8% of Nanobiotix shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -134.75%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

In the previous week, Mirum Pharmaceuticals had 40 more articles in the media than Nanobiotix. MarketBeat recorded 41 mentions for Mirum Pharmaceuticals and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.00 beat Mirum Pharmaceuticals' score of -0.04 indicating that Nanobiotix is being referred to more favorably in the news media.

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.

38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nanobiotix has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Nanobiotix presently has a consensus price target of $46.67, indicating a potential upside of 45.70%. Cogent Biosciences has a consensus price target of $53.57, indicating a potential upside of 59.72%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Nanobiotix.

Nanobiotix has higher revenue and earnings than Cogent Biosciences.

In the previous week, Cogent Biosciences had 8 more articles in the media than Nanobiotix. MarketBeat recorded 9 mentions for Cogent Biosciences and 1 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 0.15 beat Nanobiotix's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Nanobiotix has higher revenue and earnings than Scholar Rock.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nanobiotix presently has a consensus target price of $46.67, suggesting a potential upside of 45.70%. Scholar Rock has a consensus target price of $67.67, suggesting a potential upside of 31.26%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Scholar Rock.

In the previous week, Scholar Rock had 2 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Scholar Rock and 1 mentions for Nanobiotix. Scholar Rock's average media sentiment score of 0.35 beat Nanobiotix's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity.

Nanobiotix has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.